Compare DCOM & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCOM | GLUE |
|---|---|---|
| Founded | 1864 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1996 | 2021 |
| Metric | DCOM | GLUE |
|---|---|---|
| Price | $33.84 | $20.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $36.40 | $29.50 |
| AVG Volume (30 Days) | 340.3K | ★ 2.7M |
| Earning Date | 01-21-2026 | 03-19-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | ★ 329.09 | N/A |
| EPS | ★ 2.36 | 0.25 |
| Revenue | ★ $409,901,000.00 | $181,538,000.00 |
| Revenue This Year | $21.40 | $84.02 |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | ★ $14.42 | $81.29 |
| Revenue Growth | 47.45 | ★ 1112.27 |
| 52 Week Low | $23.25 | $3.50 |
| 52 Week High | $34.86 | $25.77 |
| Indicator | DCOM | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 67.76 | 48.60 |
| Support Level | $32.51 | $22.05 |
| Resistance Level | $34.86 | $23.29 |
| Average True Range (ATR) | 1.16 | 1.30 |
| MACD | 0.26 | -0.53 |
| Stochastic Oscillator | 81.70 | 12.32 |
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.